Overview: Parietal Cell Antibody IFA TestIntroduction: The Parietal Cell Antibody IFA Test detects parietal cell antibodies to diagnose autoimmune gastritis, causing stomach pain. Aligned with 2023 ACG guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune gastritis or pernicious anemia.
Other Names: Parietal Cell Ab Assay, Autoimmune Gastritis Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Parietal cell antibody testing began in the 1960s with autoimmune gastritis research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects parietal cell antibodies to diagnose autoimmune gastritis, guides treatment, and evaluates patients with stomach pain.
Test Parameters: 1. Parietal Cell Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of stomach pain or autoimmune symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document stomach pain, anemia, or history of autoimmune diseases. Include current medications, especially vitamin B12 supplements.
Consent: Written consent required, detailing the tests purpose, autoimmune gastritis implications, and risks of sample collection.
Procedural Considerations: Uses immunofluorescence assay (IFA) to detect parietal cell antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for autoimmune gastritis diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive antibodies confirm autoimmune gastritis, guiding vitamin B12 therapy. Negative results may require intrinsic factor antibody testing.
Specialist Consultation: Consult a gastroenterologist for result interpretation and treatment planning.
Additional Supporting Tests: Intrinsic factor antibody, vitamin B12 levels, or gastric biopsy to confirm autoimmune gastritis diagnosis.
Test Limitations: Non-specific for certain autoimmune conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: ACG Gastritis Guidelines, 2023; American Journal of Gastroenterology, Laine L, 2022.
